IL161674A - Methods and means for producing proteins through predetermined post-translational modifications - Google Patents

Methods and means for producing proteins through predetermined post-translational modifications

Info

Publication number
IL161674A
IL161674A IL161674A IL16167404A IL161674A IL 161674 A IL161674 A IL 161674A IL 161674 A IL161674 A IL 161674A IL 16167404 A IL16167404 A IL 16167404A IL 161674 A IL161674 A IL 161674A
Authority
IL
Israel
Prior art keywords
epo
per
cells
structures
lewis
Prior art date
Application number
IL161674A
Other languages
English (en)
Hebrew (he)
Inventor
Abraham Bout
Dirk Jan Elbertus Opstelten
Johan Christiaan Kapteyn
Petrus Christianus Johannes Josephus Passier
Ronald Hendrik Peter Brus
Original Assignee
Crucell Holland Bv
Abraham Bout
Dirk Jan Elbertus Opstelten
Johan Christiaan Kapteyn
Petrus Christianus Johannes Josephus Passier
Ronald Hendrik Peter Brus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2001/000792 external-priority patent/WO2003050286A1/fr
Priority claimed from PCT/NL2002/000257 external-priority patent/WO2003089468A1/fr
Application filed by Crucell Holland Bv, Abraham Bout, Dirk Jan Elbertus Opstelten, Johan Christiaan Kapteyn, Petrus Christianus Johannes Josephus Passier, Ronald Hendrik Peter Brus filed Critical Crucell Holland Bv
Publication of IL161674A publication Critical patent/IL161674A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
IL161674A 2001-10-29 2004-04-29 Methods and means for producing proteins through predetermined post-translational modifications IL161674A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NL2001/000792 WO2003050286A1 (fr) 2001-10-29 2001-10-29 Procedes et moyens de production de proteines a modifications post-traductionnelles
PCT/NL2002/000257 WO2003089468A1 (fr) 2002-04-19 2002-04-19 Methodes et moyens de production de proteines avec des modifications post-traductionnelles preetablies
PCT/NL2002/000686 WO2003038100A1 (fr) 2001-10-29 2002-10-29 Procedes et moyens de fabrication de proteines presentant des modifications post-traductionnelles predeterminees

Publications (1)

Publication Number Publication Date
IL161674A true IL161674A (en) 2014-06-30

Family

ID=26642018

Family Applications (3)

Application Number Title Priority Date Filing Date
IL161674A IL161674A (en) 2001-10-29 2004-04-29 Methods and means for producing proteins through predetermined post-translational modifications
IL201673A IL201673A (en) 2001-10-29 2009-10-21 A method for producing a portion of protein molecules enriched with glycans in n
IL201674A IL201674A (en) 2001-10-29 2009-10-21 Methods for producing proteins through predetermined post-translational modifications

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL201673A IL201673A (en) 2001-10-29 2009-10-21 A method for producing a portion of protein molecules enriched with glycans in n
IL201674A IL201674A (en) 2001-10-29 2009-10-21 Methods for producing proteins through predetermined post-translational modifications

Country Status (14)

Country Link
US (3) US7304031B2 (fr)
EP (2) EP1440157B1 (fr)
JP (1) JP4583029B2 (fr)
CN (1) CN100347306C (fr)
AT (1) ATE542904T1 (fr)
AU (1) AU2002335585B2 (fr)
BR (1) BR0213402A (fr)
CA (2) CA2756610C (fr)
DK (1) DK1440157T3 (fr)
EA (2) EA008220B1 (fr)
ES (1) ES2381104T3 (fr)
IL (3) IL161674A (fr)
NO (1) NO20042209L (fr)
WO (1) WO2003038100A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
CA2756610C (fr) * 2001-10-29 2015-08-25 Crucell Holland B.V. Procedes de production de proteines comportant des glycanes n-lies comprenant des structures (sialyl-) lewis x ou lacdinac
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
WO2005090390A1 (fr) * 2004-03-17 2005-09-29 Crucell Holland B.V. Nouveau dosage pour separer et quantifier des antigenes d'hemagglutinine
JP2008527980A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子
US20100040581A1 (en) * 2005-06-01 2010-02-18 Niigata Tlo Corporation Epo derivative-containing therapeutic agents for blood-related diseases
AR053416A1 (es) * 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
EP1954815B1 (fr) * 2005-11-15 2015-02-25 GlycoFi, Inc. Production de glycoproteines a o-glycosylation reduite
US7642078B2 (en) 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
WO2007098548A1 (fr) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited Molécule et chimères de cette molécule
AR061269A1 (es) 2006-06-07 2008-08-13 Chugai Pharmaceutical Co Ltd Composicion y metodo de revascularizacion para el tratamiento de enfermedades isquemicas usando eritropoyetina
CN101505788B (zh) 2006-08-22 2013-06-26 中外制药株式会社 周围神经病变的预防和/或治疗药
AR065613A1 (es) 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
BRPI0810065A2 (pt) 2007-04-16 2020-01-14 Momenta Pharmaceuticals, Inc. caracterização de n-glicanos usando exoglicosidases
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
US8138092B2 (en) 2009-01-09 2012-03-20 Lam Research Corporation Spacer formation for array double patterning
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
EP2773964A4 (fr) * 2011-11-03 2015-06-24 Stc Biolog Inc Procédé de détermination de propriétés pharmacologiques de protéines recombinantes
BR112014025951A2 (pt) 2012-04-19 2017-07-11 Opko Biologics Ltd variantes de oxintomodulina de longa ação e métodos de produção do mesmo
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
EA033788B1 (ru) 2012-11-20 2019-11-26 Opko Biologics Ltd Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
CN110256560A (zh) 2013-03-11 2019-09-20 建新公司 通过糖工程的位点特异性抗体-药物偶联
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US20180180626A1 (en) * 2014-07-01 2018-06-28 Stc Biologics, Inc. A method for development of recombinant proteins with fingerprint like similarity to the reference product
HRP20230405T8 (hr) 2014-12-10 2023-09-29 Opko Biologics Ltd. Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta
ES2893616T3 (es) 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos
MY206271A (en) 2016-07-11 2024-12-06 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
AU2017297767B2 (en) * 2016-07-12 2021-09-09 Hexal Ag Glycoprotein with reduced acetylation rate of sialic acid residues
WO2018182529A1 (fr) * 2017-03-29 2018-10-04 Agency For Science, Technology And Research Anticorps anti-oligosaccharide
WO2019075053A1 (fr) * 2017-10-11 2019-04-18 Elanco Us Inc. Variants du g-csf porcins et leurs utilisations
CN111514279B (zh) * 2020-06-16 2023-07-18 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 神经营养因子3在制备治疗男性性腺功能减退症的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ATE290091T1 (de) * 1997-03-27 2005-03-15 Univ British Columbia Insekten-expressionsvektoren
CA2221819A1 (fr) 1997-03-27 1998-09-27 Thomas A. Gigliatti Vecteurs d'expression d'insectes
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
AU784550B2 (en) 1999-04-13 2006-05-04 Kenneth S. Warren Institute, Inc., The Modulation of excitable tissue function by peripherally administered erythropoietin
US20050164386A1 (en) 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CN100457914C (zh) * 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FI109811B (fi) * 2000-09-26 2002-10-15 Medicel Oy Menetelmä GDP-L-fukoosin valmistamiseksi ja menetelmässä käytettäviä välineitä
DE10056136A1 (de) 2000-11-07 2002-05-16 Nemod New Modalities Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
EP2042196B1 (fr) * 2001-10-10 2016-07-13 ratiopharm GmbH Remodelage et glycoconjugation de facteur stimulant les colonies de granulocytes (G-CSF)
CA2756610C (fr) 2001-10-29 2015-08-25 Crucell Holland B.V. Procedes de production de proteines comportant des glycanes n-lies comprenant des structures (sialyl-) lewis x ou lacdinac
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
WO2005090390A1 (fr) 2004-03-17 2005-09-29 Crucell Holland B.V. Nouveau dosage pour separer et quantifier des antigenes d'hemagglutinine
US7183371B2 (en) * 2004-11-01 2007-02-27 General Electric Company Method for making polycarbonate
US20080139608A1 (en) 2006-12-06 2008-06-12 Universiteit Leiden 2,6,8, Trisubstituted 1-deazapurines and their different uses

Also Published As

Publication number Publication date
JP4583029B2 (ja) 2010-11-17
WO2003038100A1 (fr) 2003-05-08
EA200602163A1 (ru) 2007-04-27
EP2292770B1 (fr) 2014-11-26
EP1440157B1 (fr) 2012-01-25
EA012340B1 (ru) 2009-10-30
IL201673A (en) 2013-10-31
CN1578838A (zh) 2005-02-09
ES2381104T3 (es) 2012-05-23
US20050164917A1 (en) 2005-07-28
US7304031B2 (en) 2007-12-04
CA2756610A1 (fr) 2003-05-08
US7785833B2 (en) 2010-08-31
ATE542904T1 (de) 2012-02-15
CN100347306C (zh) 2007-11-07
EA008220B1 (ru) 2007-04-27
EP2292770A3 (fr) 2012-12-19
US7696157B2 (en) 2010-04-13
BR0213402A (pt) 2004-10-13
EP1440157A1 (fr) 2004-07-28
JP2005507426A (ja) 2005-03-17
US20070117742A1 (en) 2007-05-24
EA200400605A1 (ru) 2004-08-26
DK1440157T3 (da) 2012-05-07
CA2465007A1 (fr) 2003-05-08
NO20042209L (no) 2004-07-28
IL201674A (en) 2013-10-31
CA2465007C (fr) 2012-01-17
US20080032922A1 (en) 2008-02-07
CA2756610C (fr) 2015-08-25
AU2002335585B2 (en) 2007-08-16
EP2292770A2 (fr) 2011-03-09

Similar Documents

Publication Publication Date Title
US7785833B2 (en) Methods and means for producing proteins with predetermined post-translational modifications
AU2002335585A1 (en) Methods and means for producing proteins with predetermined post-translational modifications
Tsuda et al. Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins
KR101319733B1 (ko) 아데노바이러스 ｅ１ａ 단백질을 발현하는 세포로부터시알릴화가 증가된 재조합 단백질의 제조 방법, 및 그로인해 얻어진 단백질들
CN105906702A (zh) 包括α 2,3-和α 2,6-唾液酸化的重组FSH
EP0902085A1 (fr) Erythropoiétine humaine recombinante caractérisée par une glycosylation avantageuse
CN101177700B (zh) 生产具有预定的翻译后修饰的蛋白质的方法和手段
NZ532438A (en) Methods for producing proteinaceous molecules in a mammalian cell comprising a predetermined post-translational modification
HK1062924A1 (en) Methods and means for producing proteins with predetermined post-translational modifications
HK1062924B (en) Methods and means for producing proteins with predetermined post-translational modifications
WO2003089468A1 (fr) Methodes et moyens de production de proteines avec des modifications post-traductionnelles preetablies
CN114340653B (zh) 人重组低唾液酸化红细胞生成素、其纯化方法及治疗用途
CN101090973B (zh) 从表达腺病毒e1a蛋白的细胞中获得唾液酸化增加的重组蛋白质的方法及由此获得的蛋白质
CN116194585A (zh) 一种糖基化修饰的促红细胞生成素及其应用

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees